AstraZeneca Bevespi Aerosphere (Grombrominam/Fumotro) has been approved by Japan
-
Last Update: 2020-06-09
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
, AstraZeneca, thegiant ofPharmaceuticals(http:// in the UK, announced that Bevespi Aerosphere had been approved in Japan as a fixed-dose, long-acting double bronchial dilatatator to relieve symptoms of chronic obstructive pulmonary disease (COPD)About Bevespi AerosphereBevespi Aerosphere consists of a fixed dose of ammonium gronbrominthina (a long-acting toxin alkaloid antagonist, LAMA) and Fumaica fortero (a long-acting beta2 agonist, LABA) and is administered twice dailyBevespi Aerosphere is a LABA/LAMA compoundproduct(http://that uses Aerosphere delivery technology, and the results of the imagingtest(http://show that Bevespi Aerosphere can be effectively delivered to atmospheric and aphshesin clinical trials, Bevespi Aerosphere achieved a statistically significant improvement in lung function in COPD patients compared to two single-component and placebosBevespi Aerosphere's approval is based on data from the Phase III clinical study PINNALE 4 and the broader PIN CLINICAL programThe PINNALE 4 study enrolled 1,756 patients with moderate to very severe COPD across Asia, Europe and the United StatesThe PINNACLE clinical program involves more than 5,000 patients
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
